Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hypercoagulability and thrombosis.

R L Bick1, K Ucar

  • 1Department of Medicine, University of California, Los Angeles.

Hematology/Oncology Clinics of North America
|December 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Contaminants in heparins continue to be unfolded.

International angiology : a journal of the International Union of Angiology·2008
Same author

The rheological changes after cesarean section: The influence of low molecular weight or unfractionated heparin on the rheological properties of blood.

Clinical hemorheology and microcirculation·2007
Same author

Antiphospholipid thrombosis syndromes.

Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·2001
Same author

Stasis ulcers refractory to therapy--accelerated healing by treatment with clopidogrel +/- dalteparin: a preliminary report.

Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·2001
Same author

Proficient and cost-effective approaches for the prevention and treatment of venous thrombosis and thromboembolism.

Drugs·2000
Same author

An update on heparins at the beginning of the new millennium.

Seminars in thrombosis and hemostasis·2000
Same journal

Palliative Therapy for Liver and Biliary Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Ablative Therapies for Liver Tumors.

Hematology/oncology clinics of North America·2026
Same journal

Pathology of Liver and Biliary Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Minimally Invasive Surgery for Liver and Biliary Tract Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Surgical Considerations for Primary Liver Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Systemic Therapy for Biliary and Liver Neoplasms: Chemotherapy and Immunotherapy.

Hematology/oncology clinics of North America·2026
See all related articles

Understanding blood clotting disorders is key to preventing thrombosis. Identifying deficiencies in coagulation inhibitors and fibrinolytic factors helps diagnose hypercoagulable states and guide effective treatment.

Area of Science:

  • Hematology
  • Thrombosis Research
  • Clinical Pathology

Background:

  • Hemostasis involves a complex balance of procoagulant and anticoagulant factors.
  • Congenital and acquired alterations in hemostasis can lead to pathological thrombosis.
  • Deficiencies in coagulation inhibitors and fibrinolytic components are significant causes of hypercoagulable states.

Purpose of the Study:

  • To summarize known hemostatic alterations causing thrombosis.
  • To highlight the importance of assessing coagulation inhibitors and fibrinolytic factors.
  • To emphasize the role of laboratory assays in defining thrombotic risk.

Main Methods:

  • Review of known congenital and acquired hemostatic defects.
  • Discussion of the clinical significance of coagulation inhibitors (antithrombin III, heparin cofactor II, protein C, protein S).

Related Experiment Videos

  • Evaluation of newer assays for fibrinolytic system components (plasminogen, t-PA, t-PA inhibitor).

    • Main Results:

    • Decreases in key coagulation inhibitors are crucial in hypercoagulable states.
    • Available assays can define congenital or acquired fibrinolytic defects.
    • Laboratory testing combined with clinical evaluation can identify underlying blood protein defects in many thrombosis patients.

    Conclusions:

    • Defining the etiology of thrombotic events is vital for treatment planning.
    • Early identification of thrombotic risk factors allows for prophylactic therapy.
    • Diagnosis and counseling of affected families can prevent morbidity and mortality.